Abstract: SA-PO366
Role of Inflammation and High-Sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease and CKD: A Survey of Nephrologists
Session Information
- Hypertension, CVD, and the Kidneys: Clinical Research
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1602 Hypertension and CVD: Clinical
Authors
- Perkovic, Vlado, University of New South Wales, Sydney, New South Wales, Australia
- Cherney, David, University of Toronto, Toronto, Ontario, Canada
- Erazo Tapia, Edmundo, Novo Nordisk, Zurich, Switzerland
- Gerward, Sofia, Novo Nordisk, Copenhagen, Denmark
- Sahay, Manisha, Aditya Hospital, Abids, Hyderabad, India
- Shete, Abhijit Vilas, Novo Nordisk, Zurich, Switzerland
- Marx, Nikolaus, University Hospital RWTH Aachen, Aachen, Germany
Background
In patients (pts.) with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), systemic inflammation (SI) contributes to increased cardiovascular (CV) risk. The FLAME-ASCVD-Nephro survey assessed awareness and perception of SI among nephrologists (nephs).
Methods
An online observational study (NCT06322641) of nephs (Feb-April 2024) across 10 countries (Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, and Saudi Arabia) who treat ≥20 pts. with ASCVD+CKD a month and in practice for ≥3 years, was analyzed using descriptive statistics.
Results
Of 3,778 participants, 294 completed the survey (~30/country). Traditional CV risk factors were most often discussed with pts.; SI to a lesser extent. 78% considered burden of SI higher in pts. with both ASCVD+CKD than CKD alone, and saw SI as an independent risk factor for ASCVD (66%) and linked to the development (63%) and progression of CKD (71%). 76% agreed SI as a contributor to the risk of recurrent CV events; 67% stated residual inflammatory risk persisted despite evidence-based preventive CV therapies. 7/10 reported testing SI to assist with clinical decisions, ie how aggressively to treat ASCVD (64%) and CKD (64%), and 83% used standard CRP. 74% would like to learn more about the role of SI in ASCVD and 35% agreed inclusion of high-sensitivity C-reactive protein (hsCRP) testing in guidelines would support clinical usage.
Conclusion
This survey among nephs show SI was considered a CV risk factor, but not to the level of traditional CV risk factors. There is a need for medical education on the role of SI and guidance on hsCRP testing in pts. with ASCVD+CKD.
Funding
- Commercial Support – Novo Nordisk Health Care AG